Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reported that the FDA has granted final approval for the company's abbreviated new drug application or ANDA to market irinotecan hydrochloride injection.
Subscribe to our email newsletter
Irinotecan hydrochloride is a generic version of Pfizer’s chemotherapy agent, Camptosar injection 20mg/mL. Shipment of this product, available in 40mg/2mL and 100mg/5mL single dose vials, will begin immediately.